Heme oncology clinical research asks for more of every sample
Direct molecular counting for fusion, mutation, and resistance research
Explore the Ancora assay family for heme oncology research. Built on the Countable PCR platform, Ancora combines direct molecular counting and high-color multiplexing to support baseline characterization, longitudinal measurement, and resistance investigation.
Download the brochure to review:
- The assay portfolio, including BCR::ABL1, KMT2A-r, NPM1 Mutation, KIT D816V, PML::RARA, and ABL1 TKI Resistance Mutation Phasing
- Target coverage and research applications
- The shared Countable PCR workflow and automated reporting
- Assay kits, bundle options, and access through Countable assay services
.png)
